Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Fate Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
FATE
Nasdaq
8731
https://fatetherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Fate Therapeutics Inc
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?
- Mar 27th, 2024 3:30 pm
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
- Mar 19th, 2024 12:44 pm
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Mar 5th, 2024 9:01 pm
Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript
- Mar 1st, 2024 1:09 pm
Fate Therapeutics to Present at Upcoming March Investor Conferences
- Mar 1st, 2024 1:00 pm
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported And Analysts Have Been Lifting Their Price Targets
- Feb 29th, 2024 11:06 am
Fate Therapeutics Full Year 2023 Earnings: EPS Beats Expectations
- Feb 28th, 2024 11:02 am
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
- Feb 27th, 2024 2:16 pm
Q4 2023 Fate Therapeutics Inc Earnings Call
- Feb 27th, 2024 1:07 pm
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
- Feb 26th, 2024 10:10 pm
Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 26th, 2024 9:35 pm
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Feb 26th, 2024 9:01 pm
13 Best Booming Stocks to Buy Right Now
- Feb 21st, 2024 2:21 pm
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Feb 20th, 2024 3:00 pm
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Feb 19th, 2024 3:00 pm
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
- Feb 15th, 2024 1:00 pm
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Feb 2nd, 2024 9:01 pm
Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock?
- Jan 30th, 2024 12:54 pm
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
- Jan 8th, 2024 1:00 pm
Fate Therapeutics Insiders US$207k Short Of Breakeven On Stock Purchase
- Dec 29th, 2023 1:34 pm
Scroll